DexCom (NASDAQ:DXCM) Director Sells $296,520.00 in Stock

DexCom, Inc. (NASDAQ:DXCM) Director Mark Foletta sold 4,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the sale, the director owned 52,852 shares of the company’s stock, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

DexCom Trading Down 2.6%

NASDAQ:DXCM traded down $1.93 during mid-day trading on Wednesday, hitting $71.23. 4,301,255 shares of the stock traded hands, compared to its average volume of 5,344,921. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The stock has a market capitalization of $27.49 billion, a price-to-earnings ratio of 30.44, a PEG ratio of 1.16 and a beta of 1.45. The firm’s 50 day moving average is $66.59 and its two-hundred day moving average is $67.76.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s revenue for the quarter was up 15.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.32 earnings per share. On average, equities research analysts predict that DexCom, Inc. will post 2.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on DXCM shares. Citigroup reiterated a “buy” rating and set a $84.00 target price (up from $79.00) on shares of DexCom in a research report on Thursday, May 28th. Bank of America reduced their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Benchmark assumed coverage on shares of DexCom in a report on Monday, May 11th. They set a “buy” rating and a $77.00 price objective for the company. Stifel Nicolaus set a $90.00 price objective on shares of DexCom and gave the company a “buy” rating in a research report on Friday, June 5th. Finally, Barclays restated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a research note on Monday, May 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $84.83.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently made changes to their positions in the company. Gradient Investments LLC increased its holdings in shares of DexCom by 13.8% in the 4th quarter. Gradient Investments LLC now owns 332,006 shares of the medical device company’s stock valued at $22,035,000 after acquiring an additional 40,343 shares during the period. Nordea Investment Management AB lifted its stake in shares of DexCom by 118.6% during the 4th quarter. Nordea Investment Management AB now owns 254,315 shares of the medical device company’s stock worth $16,988,000 after purchasing an additional 137,986 shares during the last quarter. NEOS Investment Management LLC boosted its position in DexCom by 58.7% during the third quarter. NEOS Investment Management LLC now owns 175,982 shares of the medical device company’s stock valued at $11,842,000 after purchasing an additional 65,066 shares in the last quarter. Banco Santander S.A. boosted its position in DexCom by 28.9% during the third quarter. Banco Santander S.A. now owns 250,310 shares of the medical device company’s stock valued at $16,843,000 after purchasing an additional 56,062 shares in the last quarter. Finally, Banque Pictet & Cie SA grew its stake in DexCom by 58.2% in the fourth quarter. Banque Pictet & Cie SA now owns 109,823 shares of the medical device company’s stock valued at $7,289,000 after purchasing an additional 40,411 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.